The PROTECT VIII Children trial is made to determine the consequences of BAY94-9027, a recombinant human aspect VIII , when utilized as prophylaxis, dosed at least one time every week and as on-demand for severe bleeding occasions. ‘We are content that prophylaxis with this long-acting compound is currently being studied in kids young than twelve years to check our ongoing adult research. Georg Lemm, Vice President, Global Clinical Advancement Hematology, Bayer Health care. Bayer is focused on developing treatment solutions that meet up with the requirements of the hemophilia community. Whether through study, support or clinical administration, Bayer is focused on helping people with hemophilia and their own families..Farrell, M. Janechek, R. Jones .
AIAM and CHOP collaborate to develop more accurate kid crash test dummies Biomechanical Data Collection Informs Latest Advancements, Detailed in New Survey from The Children’s Hospital of Philadelphia and the Association of International Vehicle Manufacturers, Inc. A study statement released today by The Children’s Hospital of Philadelphia and the Association of International Automobile Manufacturers, Inc. details CHOP’s cutting-edge use academic and industry collaborators to build up more accurate child crash test dummies, called child anthropometric test products .